CN Patent

CN116568326A — 用于治疗实体瘤的方法及包括krasg12c抑制剂和vegf抑制剂的组合物

Assigned to Genentech Inc · Expires 2023-08-08 · 3y expired

What this patent protects

本文提供包括KRas G12C 抑制剂(例如化合物1或其药用盐)及VEGF拮抗剂(例如贝伐珠单抗)的组合疗法与使用此组合疗法的方法。

USPTO Abstract

本文提供包括KRas G12C 抑制剂(例如化合物1或其药用盐)及VEGF拮抗剂(例如贝伐珠单抗)的组合疗法与使用此组合疗法的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN116568326A
Jurisdiction
CN
Classification
—
Expires
2023-08-08
Drug substance claim
No
Drug product claim
No
Assignee
Genentech Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.